Clinical significance of CD24 as a predictor of bladder cancer recurrence

Abstract

Cluster of differentiation (CD)24 was originally described as a B lymphocyte marker and has recently received considerable attention in cancer research as its overexpression has been observed in several types of carcinoma. The CD24 molecule is a glycosyl-phosphatidylinositol-linked cell surface protein that appears to be associated with aggressive cancers involving invasion and metastasis. However, the expression of CD24 in human bladder cancer and its clinical significance remains largely unknown and no association has been reported between CD24 overexpression and human bladder tumor recurrence. In the present study, the CD24 expression in cancer tissues obtained during transurethral surgery and the subsequent intra-bladder tumor recurrence following surgery were assessed. Immunohistochemical staining was performed and the intensity of CD24 staining was semi-quantitatively evaluated. CD24 expression was observed more frequently in high-grade bladder tumors (G2–G3) than low-grade tumors (G1). Positive CD24 expression was significantly associated with intra-bladder tumor recurrence following surgery and increased staining intensity was also correlated with recurrence. The positive association between CD24 expression and tumor recurrence was observed in each tumor category (stages Ta and T1, low and high grade). The results demonstrated that CD24 expression is significantly associated with bladder tumor recurrence. To the best of our knowledge, this is the first study to reveal the significance of CD24 as a predictor of bladder cancer recurrence. These insights may lead to future therapeutic strategies targeting CD24 to prevent the dissemination of bladder cancer cells and tumor recurrence.

Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner

“…The CD24 and CD44 antigens mark distinct cell population in BC [46], and CD24 expression has been associated with a more aggressive phenotype, reduced survival and poor prognosis [47]. Metalloproteases and their inhibitors, TIMPs, play a pivotal role in BC progression.…”

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

“…Moreover, several cell-adhesion proteins 70 , such as intercellular adhesion molecule 1 (ICAM1; also known as CD54) [71][72][73] , leukocyte function-associated antigen 1 (LFA1; also known as ITGB2) 74 and CD24 (REF. 75), are overexpressed on some tumours, for which they have notable potential for use in ligand-targeted therapies 71 .…”

CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR‐ABL‐positive cells

“…Gene Ontology analysis further identified them as immune/apoptosis/cancer‐related genes. CD24 is a mucin‐like cell surface protein that is overexpressed in various cancers, such as non‐small cell lung cancer (Kristiansen et al, ), colorectal cancer (Su et al, ), bladder carcinoma (Liu et al, ), breast cancer (Kwon et al, ), and papillary thyroid carcinoma (Han et al, ). CD24 promotes cell proliferation and metastasis and inhibits apoptosis in solid tumors (Okabe et al, ; Pei et al, ).…”